Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, whereas the subgroup with negative symptoms, especially those with the residual type of schizophrenia, showed a moderate but significant 20% reduction in total scores on the Scale for the Assessment of Negative Symptoms.
Wetzel
H
H
Department of Psychiatry, University of Mainz, Germany.
Hillert
A
A
Gründer
G
G
Benkert
O
O
D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006760:Hospitalization; D006801:Humans; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy / Q000523:psychology; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D015259:Dopamine Agents; D011954:Receptors, Dopamine